Lexicon Pharmaceuticals, Inc. LXRX

Investing.com -- Shares of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) rallied over 13% in Monday morning trading following a bullish initiation of coverage from Wall Street research firm Cantor Fitzgerald. The broker set an Overweight rating and an $8.00 price target on the biopharmaceutical company, reflecting substantial upside potential driven by the company’s ongoing late-stage cardiovascular research program.

LX-9211’s novel oral, non-opioid mechanism, positive Phase II data and Phase III progress position it to address unmet neuropathic pain needs and create partnering opportunitiesDublin, Sept. 25, 2026 (GLOBE NEWSWIRE) -- "LX-9211 Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The "LX-9211 Sales Forecast and Market Size Analysis - 2034" report provides a comprehensive assessment of pilavapadin (LX-9211), Lexicon Pharmaceuticals' investigationa

THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY: Citi 2026 Biopharma Back to School Conference September 9, 2026, 11:20–11:55 AM (Eastern Time) 2026 Cantor Global Healthcare ConferenceSeptember 10, 2026, 3:20–3:50 PM (Eastern Time) H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 14, 2026, 9:00–9:30 AM (Eas

Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart FailureTHE WOODLANDS, Texas, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy and safety of sotagliflozin across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure. The data, which were presented yesterday at ESC Congres

Lexicon announced the payment after Novo Nordisk hit a key patient-dosing target in the early-stage trial of LX9851.

Novo Nordisk (CPSE:NOVO B) and Lexicon Pharmaceuticals reached a key milestone in the development of first in class oral obesity drug LX9851. Lexicon received a milestone payment from Novo Nordisk tied to clinical progress for LX9851 in obesity and metabolic disorders. The advancement of LX9851 adds a new mechanism of action to Novo Nordisk's obesity pipeline alongside its existing treatments. The update underscores ongoing efforts to address obesity as a major global health challenge with...

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales THE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S foll

Recently published Hypertrophic Cardiomyopathy Market Insights report includes a comprehensive understanding of current treatment practices, hypertrophic cardiomyopathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

In early August 2026, Lexicon Pharmaceuticals reported second-quarter results showing revenue of US$692,000 versus US$28.87 million a year earlier, alongside a shift from net income of US$3.25 million to a net loss of US$31.78 million and wider per-share losses. On the same day, the company filed two shelf registrations totaling about US$44.73 million in common stock capacity, highlighting both the strain on its current financial position and its intention to preserve flexibility for future...

Lexicon Pharmaceuticals Inc (LXRX) advances its pipeline with strong cash position despite a challenging quarter marked by a net loss and reduced revenues.

Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA® in type 1 diabetes nearing completion Phase 1 clinical development of LX9851 ongoing by Novo Nordisk Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2026, and provided an update on key corporate milestones and ac

THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s we